Spots Global Cancer Trial Database for Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer
Official Title: A Randomized, Open Label Phase II Study of OSI-211 vs Topotecan in Patients With Advanced and/or Recurrent Epithelial Ovarian Cancer
Study ID: NCT00046800
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to estimate the efficacy and safety of OSI-211 and topotecan in patients with relapsed epithelial ovarian cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
NYU- Kaplan Comprehensive Cancer Center, New York, New York, United States
The Sarah Cannon Cancer Center, Centennial Medical Center, Nashville, Tennessee, United States
St Chad's Unit, Birmingham, , United Kingdom
Beatson Oncology Centre, Glasgow, , United Kingdom
Royal Surrey County Hospital, Guildford, Surrey, , United Kingdom
Royal Marsden NHS Trust, London, , United Kingdom
Northern Centre for Cancer Research, Newcastle General Hospital, Newcastle-upon-Tyne, , United Kingdom
Mount Vernon Hospital, Northwood, Middlesex, , United Kingdom
CRC Department of Medical Oncology, Sutton Surrey, , United Kingdom
Taunton & Somerset Hospital, Taunton, , United Kingdom
Medical Oncology Unit, Torbay District General Hospital, Torquay, , United Kingdom
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
